Treated behavioral symptoms and mortality in medicare beneficiaries in nursing homes with Alzheimer's disease and related dementias

Journal of the American Geriatrics Society

Volumn 63, Issue 9, 2015, Pages 1757-1765

  Huang, Ting Ying ^a   Wei, Yu Jung ^a   Moyo, Patience ^a   Harris, Ilene ^b   Lucas, Judith A ^c   Simoni Wastila, Linda ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b IMPAQ International LLC   (United States)

^c Seton Hall University College of Nursing   (United States)

Author keywords

antipsychotics; behavioral symptoms; dementia; Medicare; nursing home

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AGED; AGGRESSIVE BEHAVIORAL SCALE; ALZHEIMER DISEASE; ANXIETY DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHALLENGING BEHAVIORAL PROFILE; COHEN MANSFIELD AGITATION INVENTORY; COHORT ANALYSIS; CONFERENCE PAPER; DELIRIUM; DEMENTIA; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICARE; MOOD DISORDER; MORTALITY; NURSING HOME PATIENT; PSYCHOPHYSIOLOGIC ASSESSMENT; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT RESPONSE; BEHAVIOR; COMPLICATION; ETIOLOGY; NURSING HOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MEDICARE; NURSING HOMES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84942191577     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13606     Document Type: Conference Paper

References (50)

1. Eden J, Maslow K, Le M, et al., eds. The Mental Health and Substance Use Workforce for Older Adults: In Whose Hands? Washington, DC: National Academies Press, 2012.
2. Chan DC, Kasper JD, Black BS, et al., Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: The Memory and Medical Care Study. Int J Geriatr Psychiatry 2003; 18: 174-182.
3. Lyketsos CG, Lopez O, Jones B, et al., Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the Cardiovascular Health Study. JAMA 2002; 288: 1475-1483.
4. Nazir A, Arling G, Perkins AJ, et al., Monitoring quality of care for nursing home residents with behavioral and psychological symptoms related to dementia. J Am Med Dir Assoc 2011; 12: 660-667.
5. Jönsson L, Eriksdotter Jönhagen M, Kilander L, et al., Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 449-459.
6. Voyer P, Verreault R, Azizah GM, et al., Prevalence of physical and verbal aggressive behaviours and associated factors among older adults in long-term care facilities. BMC Geriatr 2005; 5: 13.
7. Black W, Almeida OP,. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr 2004; 16: 295-315.
8. Boustani M, Zimmerman S, Williams CS, et al., Characteristics associated with behavioral symptoms related to dementia in long-term care residents. Gerontologist 2005; 45 (Suppl 1): 56-61.
9. Kales HC, Gitlin LN, Lyketsos CG, et al., Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr Soc 2014; 62: 762-769.
10. A Guide to the Management of Psychotic Disorders and Neuropsychiatric Symptoms of Dementia in Older Adults. The American Geriatrics Society, 2011 [on-line]. Available at http://dementia.americangeriatrics.org/AGSGeriPsychConsult.pdf Accessed March 23, 2014.
11. Drouillard N, Mithani A, Chan PKY,. Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly. B C Med J 2013; 55: 90-95.
12. Schneider LS, Dagerman KS, Insel P,. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
13. Gill SS, Bronskill SE, Normand S-LT, et al., Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-786.
14. Schneider LS, Dagerman K, Insel PS,. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210.
15. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. The Food and Drug Administration, 2005 [on-line]. Available at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm053171.htm Accessed January 15, 2014.
16. Information for Healthcare Professionals: Conventional Antipsychotics. The Food and Drug Administration, 2008 [on-line]. Available at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm Accessed January 15, 2014.
17. Jeste DV, Blazer D, Casey D, et al., ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2007; 33: 957-970.
18. Kuehn BM,. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293: 2453-2462.
19. Kales H, Valenstein M, Kim H, et al., Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164: 1568-1576.
20. Zivin K, Pfeiffer PN, Bohnert AS, et al., Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170: 642-650.
21. Seitz DP, Adunuri N, Gill SS, et al., Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; 2: CD008191.
22. Porsteinsson AP, Drye LT, Pollock BG, et al., Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014; 311: 682-691.
23. CCWdata.org. The Chronic Conditions Data Warehouse [on-line]. Available at https://www.ccwdata.org Accessed January 21, 2014.
24. Long Term Care Minimum Data Set (MDS). The Centers for Medicare and Medicaid Services, 2012 [on-line]. Available at http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for Order/IdentifiableDataFiles/LongTermCareMinimumDataSetMDS.html Accessed January 15, 2014.
25. Bharucha AJ, Vasilescu M, Dew MA, et al., Prevalence of behavioral symptoms: Comparison of the Minimum Data Set assessments with research instruments. J Am Med Dir Assoc 2008; 9: 244-250.
26. Saliba D, Buchanan J,. Development and Validation of a Revised Nursing Home Assessment Tool: MDS 3.0. Santa Monica, CA: Rand Corporation Health, 2008.
27. Wei Y-J, Simoni-Wastila L, Zuckerman IH, et al., Algorithm for identifying nursing home days using Medicare claims and Minimum Data Set assessment data. Med Care 2014; Mar 13. [Epub ahead of print].
28. Ray WA,. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158: 915-920.
29. Pope GC, Kautter J, Ellis RP, et al., Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004; 25: 119-141.
30. Morris JN, Fries BE, Morris SA,. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci 1999; 54A: M546-M553.
31. Hartmaier SL, Sloane PD, Guess HA, et al., The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set. J Am Geriatr Soc 1994; 42: 1173-1179.
32. Hirdes JP, Frijters DH, Teare GF,. The MDS-CHESS Scale: A new measure to predict mortality in institutionalized older people. J Am Geriatr Soc 2003; 51: 96-100.
33. Lester P, Kohen I, Stefanacci RG, et al., Antipsychotic drug use since the FDA black box warning: Survey of nursing home policies. J Am Med Dir Assoc 2011; 12: 573-577.
34. Desai VC, Heaton PC, Kelton CM,. Impact of the Food and Drug Administration's antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimers Dement 2012; 8: 453-457.
35. Kales HC, Zivin K, Kim HM, et al., Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011; 68: 190-197.
36. Initiative to Improve Behavioral Health and Reduce the Use of Antipsychotic Medications in Nursing Homes Residents Video Streaming Event. Centers for Medicare and Medicaid Services, 2012 [on-line]. Available at http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/Spotlight.html Accessed January 15, 2014.
37. Schneider LS, Tariot PN, Dagerman KS, et al., Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-1538.
38. Sultzer D, Davis S, Tariot P, et al., Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165: 844-854.
39. Aalten P, de Vugt ME, Jaspers N, et al., The course of neuropsychiatric symptoms in dementia. Part I: Findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 2005; 20: 523-530.
40. Ballard CG, Thomas A, Fossey J, et al., A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004; 65: 114-119.
41. Ballard C, Hanney ML, Theodoulou M, et al., The Dementia Antipsychotic Withdrawal Trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151-157.
42. Ballard C, Lana MM, Theodoulou M, et al., A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 5: e76.
43. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al., The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005; 165: 1280-1285.
44. Simoni-Wastila L, Ryder PT, Qian J, et al., Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17: 417-427.
45. Wei Y-J, Simoni-Wastila L, Zuckerman IH, et al., Quality of psychopharmacological medication prescribing and mortality in Medicare beneficiaries in nursing homes. J Am Geriatr Soc 2014; 62: 1490-1504.
46. Kales HC, Kim HM, Zivin K, et al., Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169: 71-79.
47. Cummings JL, Mega M, Gray K, et al., The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2308.
48. Cohen-Mansfield J, Marx MS, Rosenthal AS,. A description of agitation in a nursing home. J Gerontol 1989; 44: M77-M84.
49. Gerritsen D, Achterberg W, Steverink N, et al., The MDS Challenging Behavior Profile for long-term care. Aging Ment Health 2008; 12: 116-123.
50. Perlman CM, Hirdes JP,. The Aggressive Behavior Scale: A new scale to measure aggression based on the Minimum Data Set. J Am Geriatr Soc 2008; 56: 2298-2303.